In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Seaside Therapeutics LLC

http://www.seasidetherapeutics.com/

Latest From Seaside Therapeutics LLC

Keeping Track: Sanofi Submits Lixisenatide NDA (Again); Sandoz Files Second Biosimilar Application

The latest drug development news and highlights from our FDA Performance Tracker.

BioPharmaceutical United States

INTERVIEW: Alcobra CEO discusses novel ADHD path

Alcobra CEO Yaron Daniely admits that drug development for attention deficit hyperactivity disorder (ADHD) is a "road well-traveled," but says his Tel Aviv, Israel-based company is forging a new path and will confirm the efficacy of its drug metadoxine (MDX) around the end of September.

Neurology Israel

Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?

The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.

BioPharmaceutical Research and Development Strategies

Stem Cell System Shows How Gene Silencing Causes Fragile X Syndrome

Using stem cells, researchers have shown that the gene mutation that causes fragile X leads to gene silencing through the binding of a small repeat mRNA transcript to the gene itself. They further show that a small molecule can disrupt this RNA-DNA duplex, preventing the disease from occurring and suggesting a potential prenatal therapy.

BioPharmaceutical Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register